

Angela B Mariotto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8341066/angela-b-mariotto-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

20,876
citations

50
h-index

99
g-index

99
ext. papers

25,043
ext. citations

16.4
avg, IF

6.95
L-index

#	Paper	IF	Citations
96	Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality.. <i>BMC Public Health</i> , 2022 , 22, 141	4.1	1
95	Survivorship for Individuals Living with Advanced and Metastatic Cancers: National Cancer Institute Meeting Report. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
94	Cancer prevalence by phase of care: an indicator for assessing health service needs. <i>Tumori</i> , 2021 , 107, 311-317	1.7	1
93	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1336-1342	9.7	6
92	Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 641-653	5.2	0
91	Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	10
90	Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016. <i>Cancer</i> , 2021 , 127, 4277-4286	6.4	7
89	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 2001-2009	4	1
88	Medical Care Costs Associated with Cancer Survivorship in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1304-1312	4	82
87	Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database. <i>JAMA Network Open</i> , 2020 , 3, e200452	10.4	17
86	Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1013-1020	9.7	14
85	Estimating Chemotherapy Use Among Patients With a Prior Primary Cancer Diagnosis Using SEER-Medicare Data. <i>Journal of the National Cancer Institute Monographs</i> , 2020 , 2020, 14-21	4.8	1
84	Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries. <i>Journal of the National Cancer Institute Monographs</i> , 2020 , 2020, 31-38	4.8	3
83	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. <i>New England Journal of Medicine</i> , 2020 , 383, 640-649	59.2	283
82	Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History?. <i>Journal of the National Cancer Institute Monographs</i> , 2020 , 2020, 22-30	4.8	8
81	Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 154-160	9.7	15
80	Analyzing discrete competing risks data with partially overlapping or independent data sources and nonstandard sampling schemes, with application to cancer registries. <i>Statistics in Medicine</i> , 2019 , 38, 5528-5546	2.3	1

79	Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1544-1551	4	12
78	Cancer treatment and survivorship statistics, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019 , 69, 363-385	220.7	1873
77	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1305-1315	2.2	126
76	Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions. <i>Cancer Epidemiology</i> , 2018 , 54, 12-18	2.8	6
75	Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. <i>PLoS ONE</i> , 2018 , 13, e0201034	3.7	23
74	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. <i>Cancer</i> , 2018 , 124, 1197-1206	6.4	41
73	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 1332-1341	4	17
72	Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. <i>Cancer</i> , 2018 , 124, 2801-2814	6.4	140
71	Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). <i>Journal of Clinical Oncology</i> , 2017 , 35, 529-535	2.2	38
70	Is prostate cancer different in black men? Answers from 3 natural history models. <i>Cancer</i> , 2017 , 123, 2312-2319	6.4	57
69	Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. <i>Cancer</i> , 2017 , 123, 3326-3334	6.4	32
68	Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 809-815	4	249
67	Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	778
66	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2017 , 167, 449-455	8	108
65	The history and use of cancer registry data by public health cancer control programs in the United States. <i>Cancer</i> , 2017 , 123 Suppl 24, 4969-4976	6.4	57
64	Comparison of SEER Treatment Data With Medicare Claims. <i>Medical Care</i> , 2016 , 54, e55-64	3.1	266
63	Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. <i>Medical Care</i> , 2016 , 54, e47-54	3.1	42
62	Cancer treatment and survivorship statistics, 2016. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 271-89	220.7	3256

61	Expected population impacts of discontinued prostate-specific antigen screening. <i>Cancer</i> , 2014 , 120, 3519-26	6.4	60
60	Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. <i>Cancer</i> , 2014 , 120, 1290-314	6.4	829
59	Cancer treatment and survivorship statistics, 2014. <i>Ca-A Cancer Journal for Clinicians</i> , 2014 , 64, 252-71	220.7	2141
58	Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. <i>Annals of Internal Medicine</i> , 2014 , 161, 104-12	8	91
57	The impact of state-specific life tables on relative survival. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 218-27	4.8	13
56	Cancer survival: an overview of measures, uses, and interpretation. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 145-86	4.8	118
55	When do changes in cancer survival mean progress? The insight from population incidence and mortality. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 187-97	4.8	91
54	Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 244-54	4.8	9
53	Evaluation of North American Association of Central Cancer Registries (NAACCR) data for use in population-based cancer survival studies. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 198-209	4.8	55
52	Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 255-64	4.8	58
51	Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. <i>Journal of Clinical Epidemiology</i> , 2013 , 66, 1376-85	5.7	39
50	Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. <i>American Journal of Epidemiology</i> , 2013 , 178, 339-49	3.8	100
49	Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. <i>Journal of the National Cancer Institute Monographs</i> , 2013 , 2013, 1-6	4.8	10
48	Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. <i>Journal of the National Cancer Institute Monographs</i> , 2013 , 2013, 88-98	4.8	9
47	Comparing cancer care, outcomes, and costs across health systems: charting the course. <i>Journal of the National Cancer Institute Monographs</i> , 2013 , 2013, 124-30	4.8	24
46	Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 561-70	4	464
45	Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. <i>Annals of Internal Medicine</i> , 2013 , 159, 667-76	8	100
44	Development of a prognostic model for six-month mortality in older adults with declining health. <i>Journal of Pain and Symptom Management</i> , 2012 , 43, 527-39	4.8	34

43	Cancer treatment and survivorship statistics, 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012 , 62, 220-41	220.7	2114
42	The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. <i>Cancer</i> , 2012 , 118, 5652-62	6.4	27
41	The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. <i>Cancer</i> , 2012 , 118, 5955-63	6.4	100
40	The impact of PLCO control arm contamination on perceived PSA screening efficacy. <i>Cancer Causes and Control</i> , 2012 , 23, 827-35	2.8	50
39	Productivity savings from colorectal cancer prevention and control strategies. <i>American Journal of Preventive Medicine</i> , 2011 , 41, e5-e14	6.1	24
38	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 1412-7	5.7	37
37	Economic burden of cancer in the United States: estimates, projections, and future research. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2006-14	4	309
36	Projections of the cost of cancer care in the United States: 2010-2020. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 117-28	9.7	1738
35	Cancer survivors: a booming population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1996-2005	4	315
34	Improved estimates of cancer-specific survival rates from population-based data. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1584-98	9.7	325
33	Burden of illness in adult survivors of childhood cancers: findings from a population-based national sample. <i>Cancer</i> , 2010 , 116, 3712-21	6.4	37
32	Long-term survivors of childhood cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 1033-40	4	272
31	Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 374-83	9.7	572
30	Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015. <i>Cancer</i> , 2009 , 115, 1954-66	6.4	52
29	Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts. <i>Cancer</i> , 2009 , 115, 5272-83	6.4	39
28	Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. <i>Medical Care</i> , 2009 , 47, S56-63	3.1	59
27	Adverse events after outpatient colonoscopy in the Medicare population. <i>Annals of Internal Medicine</i> , 2009 , 150, 849-57, W152	8	300
26	Overview of US Prostate Cancer Trends in the Era of PSA Screening 2009 , 3-14		1

25	Quantifying the role of PSA screening in the US prostate cancer mortality decline. <i>Cancer Causes and Control</i> , 2008 , 19, 175-81	2.8	275
24	Cost of care for elderly cancer patients in the United States. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 630-41	9.7	537
23	Current and future utilization of services from medical oncologists. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3242-7	2.2	91
22	Estimating complete prevalence of cancers diagnosed in childhood. <i>Statistics in Medicine</i> , 2008 , 27, 990-1007	10.7	9
21	Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?. <i>Cancer</i> , 2008 , 112, 2289-300	6.4	54
20	Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. <i>Health Economics (United Kingdom)</i> , 2008 , 17, 947-59	2.4	68
19	Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. <i>Cancer</i> , 2007 , 109, 1877-86	6.4	72
18	Multiple cancer prevalence: a growing challenge in long-term survivorship. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 566-71	4	191
17	Estimates of long-term survival for newly diagnosed cancer patients: a projection approach. <i>Cancer</i> , 2006 , 106, 2039-50	6.4	13
16	Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. <i>Journal of the National Cancer Institute Monographs</i> , 2006 , 7-15	4.8	48
15	Estimating the variance of cancer prevalence from population-based registries. <i>Statistical Methods in Medical Research</i> , 2006 , 15, 235-53	2.3	12
14	Changing patterns in breast cancer incidence trends. <i>Journal of the National Cancer Institute Monographs</i> , 2006 , 19-25	4.8	87
13	Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. <i>Cancer Causes and Control</i> , 2006 , 17, 1215-26	2.8	51
12	Geographic association between mammography use and mortality reduction in the US. <i>Cancer Causes and Control</i> , 2005 , 16, 691-9	2.8	17
11	The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. <i>Statistical Methods in Medical Research</i> , 2004 , 13, 421-42	2.3	35
10	An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. <i>American Journal of Epidemiology</i> , 2004 , 160, 1059-69	3.8	32
9	The prevalence of patients with colorectal carcinoma under care in the U.S. <i>Cancer</i> , 2003 , 98, 1253-61	6.4	19
8	Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. <i>Cancer</i> , 2002 , 95, 870-80	6.4	29

7	Projecting SEER cancer survival rates to the US: an ecological regression approach. <i>Cancer Causes and Control</i> , 2002 , 13, 101-11	2.8	57
6	Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1626-34	9.7	109
5	Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program. <i>International Journal of Epidemiology</i> , 2000 , 29, 197-207	7.8	89
4	A back-calculation method to estimate the age and period HIV infection intensity, considering the susceptible population. <i>Statistics in Medicine</i> , 1995 , 14, 1513-30	2.3	13
3	Comparisons of colon-cancer survival among European countries: The Eurocare Study. <i>International Journal of Cancer</i> , 1995 , 63, 43-8	7.5	59
2	Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. <i>American Journal of Epidemiology</i> , 1992 , 135, 428-37	3.8	77
1	Cancer treatment and survivorship statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> ,	220.7	46